MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Hologic pulls Vitalia handpieces, probes in light of FDA concerns over vaginal rejuv tech

Hologic pulls Vitalia handpieces, probes in light of FDA concerns over vaginal rejuv tech

By

Hologic

Hologic (NSDQ:HOLX) said today that its subsidiary Cynosure is suspending marketing and distribution of its TempSure Vitalia handpieces and probes after the FDA released a warning about a lack of evidence to support certain “vaginal rejuvenation” products late last month.

The Marlborough, Mass.-based company said that it takes “the FDA’s recent statements very seriously” and that it is suspending sales of the device “until it has confirmed they meet all regulatory requirements for devices in this category.”

Hologic said it is reaching out to customers to return any Vitalia handpieces and unused probes that have been purchased so far, and added that it has not received any reports of adverse effects associated with the use of the device.

The company also said that it received a letter from the FDA late last month related into its MonaLisa Touch laser, but did not state any plans to halt distribution or marketing of the device.

“This action is limited to the Vitalia probe and handpiece and does not affect other Hologic gynecology products such as the MonaLisa Touch laser. In addition, the TempSure System remains FDA-cleared and may continue to be used with its various other handpieces, including TempSure Envi,” Hologic wrote in an SEC filing.

Hologic said that it previously forecast approximately $7 million in revenue associated with the TempSure Vitalia for the fourth quarter of this year, and that any returns of the devices are expected to be recorded as a reduction to revenue, primarily during the fourth quarter.

“Because the number of these returns is uncertain, Hologic is not able to accurately forecast the financial effect, including any potential impact on the full-year and fourth-quarter financial guidance provided on July 31, 2018, of these decisions at this time,” the company wrote in an SEC filing.

The returns should only serve as “an incremental setback” for the company’s Cynosure aesthetics division, according to Leerink Partners analyst Richard Newitter.

Newitter said that Cynosure has been “struggling for the last 12 months” and that the suspension will likely push back the re-acceleration trajectory of the subsidiary even further.

Hologic has been looking to advance its Cynosure division, which it acquired last March for $1.7 billion, in an effort to expand its focus on women’s health into the cosmetic and aesthetics market.

In case you missed it

RSS From Medical Design & Outsourcing

  • Ahead of G7 launch, Dexcom CEO plans for ‘more activity than we’ve ever seen’ in 2022
    With a major product approval and launch in its sights, Dexcom prepares for a big year in 2022. Across 2021, Dexcom (NSDQ:DXCM) took several steps forward. The company touted its next-generation G7 continuous glucose monitor (CGM) and announced a major regulatory nod and partnership for real-time application programming interfaces (APIs), to list a couple. As the new year gets underway, expectations for the… […]
  • Former Zimmer Biomet executive has a new job
    Carrie Nichol, the former chief accounting officer of Zimmer Biomet (NYSE:ZBH), has a new job outside of the medtech industry. Nichol, who also served as vice president, controller and principal accounting officer at Zimmer Biomet, is now a VP and controller at Minnetonka, Minnesota-based Cargill. Her departure was among the many notable medtech executive moves… […]
  • Employees say Intuitive, Boston Scientific, J&J, Medtronic are among the best places to work in 2022
    Intuitive Surgical, Boston Scientific, Johnson & Johnson and Medtronic were recently named by Glassdoor as Best Places to Work in 2022 based on employee reviews. Each year, Glassdoor uses feedback that employees have shared on the website over the past 12 months to compile a list of the best places to work for the upcoming… […]
  • Medtronic’s M&A strategy explained by CFO Karen Parkhill
    When Medtronic CFO and EVP Karen Parkhill looks back at the medical device manufacturer’s performance through the COVID-19 pandemic, she recalls a key decision that rankled investors but paid off in the long run. “When I first joined Medtronic, it was shortly after the Covidien merger and we had taken on a lot of debt… […]
  • Loftware acquires Prisym ID
    Loftware announced that it acquired Prisym ID, a provider of regulated content and label management solutions. Prisym ID focuses on clinical trials, medical device and pharmaceutical labeling, with the acquisition set to expand Loftware’s enterprise labeling solution offerings for the medical device and pharmaceutical industries while enhancing Loftware’s end-to-end, cloud-based labeling platform with advanced clinical… […]
  • BD, Pfizer, Wellcome want to improve hospitals’ antimicrobial practices
    BD (NYSE:BDX) announced yesterday that it will collaborate with Pfizer (NYSE:PFE) and Wellcome to advance antimicrobial stewardship practices. The collaboration builds on ongoing efforts to advance the role of diagnostics in addressing the challenge of antimicrobial resistance (AMR), according to a news release. The companies will survey existing diagnostic practices to highlight benefits and gaps… […]
  • iRhythm CEO considers costs on the path to profitability
    Fresh off positive reimbursement news for its Zio remote external electrocardiogram monitoring device, the CEO of iRhythm Technologies (NSDQ:IRTC) doesn’t just have revenue on his mind. iRhythm President and CEO Quentin Blackford — the former Dexcom COO who replaced Mike Coyle in September — said his company will need to keep costs under control as it… […]
  • Integer Holdings makes additions to its executive team
    Integer Holdings today announced that it has appointed three new executives to its leadership team. The appointments come as part of a planned transition due to retirements. Margaret Cathy is being promoted to senior VP of quality and regulatory affairs; Andrew Senn is being promoted to senior VP of strategy and business development and McAlister… […]
  • Healthcare venture funding boomed in 2021; expect a slowdown in 2022
    An all-time-high $86 billion of venture capital investments in the U.S. and Europe last year bested 2020’s record haul by more than 30% and grew more than 150% from 2019, according to a new analysis by Silicon Valley Bank. After record-setting quarters in the first half, however, VC investment slowed due to poor performing biopharma… […]
  • Medical technical writers vs. medical writers: What’s the difference?
    By CfPIE Pharmaceutical organizations often have trouble conveying complex medical concepts to “layman” users like patients and the public. Being able to communicate medical device usage instructions, clinical trial results, patient education materials, and other important materials is essential for end-users to get the most out of your products and services while preventing potential health… […]
  • Traco Power touts new encapsulated AC/DC power supplies
    Traco Power this week announced it launched its new TPP 40E and TPP 65E miniature encapsulated AC/DC power supplies. The new AC/DC power supplies have safety approvals for both medical and industrial applications. Each wattage family has six models, offering single outputs of 5, 12, 15, 24, 36, 48V with up to 94% efficiency, according… […]